Articles by Jill Wechsler - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Jill Wechsler

Campaign Mounts to Curb Counterfeit Drugs

Manufacturers and regulators struggle to control phony versions of crucial medicines.
Sep 1, 2012

Manufacturers and regulators struggle to control phony versions of crucial medicines.

FDA User-Fee Legislation

Import controls and risk strategies aim to promote quality and spur new drug development.
Aug 1, 2012

Import controls and risk strategies aim to promote quality and spur new drug development.

Healthcare Reform and Next Steps for BioPharma

Now that the Supreme Court has upheld the Affordable Care Act, what's next for biopharma?
Aug 1, 2012

Now that the Supreme Court has upheld the Affordable Care Act, what's next for biopharma?

Commentary: International AIDS Conference Highlights ARV Advances

Jul 31, 2012

Biotech Innovation Gains Support in Washington

Multiple initiatives are moving forward to maintain US leadership in biopharm R&D.
Jul 1, 2012

Multiple initiatives are moving forward to maintain US leadership in biopharm R&D.

Commentary: Healthcare Reform is Ruled Constitutional

What's next for biotech?
Jun 29, 2012

In a 5–4 vote, the Supreme Court has ruled in favor of the Constitutionality of the Affordable Care Act.

Interview with FDA: Adopting New Strategies to Oversee Global Economy

In a special anniversary interview, Washington Editor Jill Wechsler speaks with with FDA Deputy Commissioner Deborah Autor about where the agency is headed.
Jun 1, 2012

In a special anniversary interview, Washington Editor Jill Wechsler speaks with with FDA Deputy Commissioner Deborah Autor about where the agency is headed.

FDA Explores Options to Expand Access to NonPrescription Drugs

Manufacturers seek clear path to develop safe-use approaches for more risky OTC therapies.
May 1, 2012

Manufacturers seek clear path to develop safe-use approaches for more risky OTC therapies.

Manufacturers Wrestle with Drug Abuse and Critical Shortages

Soaring opioid use creates challenges for new drug development and supply-chain control.
Apr 1, 2012

Soaring opioid use creates challenges for new drug development and supply-chain control.

ADVERTISEMENT

ADVERTISEMENT

Click here